Literature DB >> 15682283

Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

B P Howden1, P B Ward, P D R Johnson, P G P Charles, M L Grayson.   

Abstract

Low-level vancomycin resistance in Staphylococcus aureus has emerged as a clinical problem over the past 8 years. The clinical relevance of this resistance has been questioned, and laboratory detection remains difficult and time consuming. There is, however, increasing evidence linking low-level vancomycin resistance with glycopeptide treatment failure in serious Staphylococcus aureus infections. Diagnostic laboratories and clinicians need to be aware of this resistance phenotype, to have procedures in place to detect the resistance, and to have strategies for managing patients with infections caused by resistant strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682283     DOI: 10.1007/s10096-004-1261-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin.

Authors:  Pamela A Moise; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method.

Authors:  M Kuroda; K Kuwahara-Arai; K Hiramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-03-16       Impact factor: 3.575

3.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

4.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

5.  Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.

Authors:  S K Hubert; J M Mohammed; S K Fridkin; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 6.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

7.  Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.

Authors:  G L Cartolano; M Cheron; D Benabid; M Leneveu; A Boisivon
Journal:  Clin Microbiol Infect       Date:  2004-05       Impact factor: 8.067

8.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

View more
  11 in total

1.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?

Authors:  Benjamin P Howden; Patrick G P Charles; Paul D R Johnson; Peter B Ward; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Two new colorimetric methods for early detection of vancomycin and oxacillin resistance in Staphylococcus aureus.

Authors:  Ahmet Y Coban; Bülent Bozdogan; Cigdem Cekic Cihan; Ebru Cetinkaya; Kemal Bilgin; Ozge Darka; Alper Akgunes; Belma Durupinar; Peter C Appelbaum
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein δ pathway.

Authors:  Chunguang Yan; Peter A Ward; Ximo Wang; Hongwei Gao
Journal:  FASEB J       Date:  2013-04-12       Impact factor: 5.191

6.  Prospective study on antibiotics misuse among infants with upper respiratory infections.

Authors:  Manal F El Sayed; Hala Tamim; Diana Jamal; Ghina Mumtaz; Imad Melki; Khalid Yunis
Journal:  Eur J Pediatr       Date:  2008-09-02       Impact factor: 3.183

7.  Vancomycin heteroresistance in bloodstream isolates of Staphylococcus capitis.

Authors:  Danaë D'mello; Andrew J Daley; Muhammad Shihab Rahman; Yue Qu; Suzanne Garland; Christopher Pearce; Margaret A Deighton
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

8.  Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Authors:  Anne Yusof; Anette Engelhardt; Asa Karlsson; Lina Bylund; Pamela Vidh; Karen Mills; Mandy Wootton; Timothy R Walsh
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

Review 9.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury.

Authors:  Chunguang Yan; Peter F Johnson; Huifang Tang; Yan Ye; Min Wu; Hongwei Gao
Journal:  Am J Pathol       Date:  2012-11-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.